Article in Journal of the American Society of Nephrology : JASN, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
14 authors.
Alfonso EirinDivision of Nephrology and Hypertension, Department of Medicine, Mayo Clinic, Rochester, Minnesota.ORCID 0000-0002-3864-9644
Sarosh SiddiqiDivision of Nephrology and Hypertension, Department of Medicine, Mayo Clinic, Rochester, Minnesota.ORCID 0009-0001-2788-5895
Autumn G HughesDivision of Nephrology and Hypertension, Department of Medicine, Mayo Clinic, Rochester, Minnesota.ORCID 0009-0003-6738-8222
Yamei JiangDivision of Nephrology and Hypertension, Department of Medicine, Mayo Clinic, Rochester, Minnesota.ORCID 0000-0002-7709-7328
Xiang-Yang ZhuDivision of Nephrology and Hypertension, Department of Medicine, Mayo Clinic, Rochester, Minnesota.ORCID 0009-0005-2571-5760
Sara KazeminiaDivision of Nephrology and Hypertension, Department of Medicine, Mayo Clinic, Rochester, Minnesota.ORCID 0000-0002-2621-9962
Bo LuDivision of Nephrology and Hypertension, Department of Medicine, Mayo Clinic, Rochester, Minnesota.
Li XingDivision of Nephrology and Hypertension, Department of Medicine, Mayo Clinic, Rochester, Minnesota.ORCID 0000-0003-0183-8000
Brandon LuDivision of Nephrology and Hypertension, Department of Medicine, Mayo Clinic, Rochester, Minnesota.ORCID 0009-0003-6438-4074
Hui TangDivision of Nephrology and Hypertension, Department of Medicine, Mayo Clinic, Rochester, Minnesota.
Ailing XueDivision of Nephrology and Hypertension, Department of Medicine, Mayo Clinic, Rochester, Minnesota.
Amir LermanDepartment of Cardiovascular Diseases, Mayo Clinic, Rochester, Minnesota.ORCID 0000-0002-9446-5313
Stephen C TextorDivision of Nephrology and Hypertension, Department of Medicine, Mayo Clinic, Rochester, Minnesota.
Lilach O LermanDivision of Nephrology and Hypertension, Department of Medicine, Mayo Clinic, Rochester, Minnesota.ORCID 0000-0002-3271-3887
Funding
Tissue Oxygenation in Human Renovascular HypertensionP01HL085307 · NHLBI · MAYO CLINIC ROCHESTER · PI ROMERO, JUAN C · 2007 to 2011
$10.4M
Obesity-induced dysfunction of human MSC in peripheral microvascular repairR01HL158691 · NHLBI · MAYO CLINIC ROCHESTER · PI Alfonso Eirin, Lilach O Lerman · 2022 to 2026
$3.4M
Hypoxia and inflammatory injury in human renovascular hypertensionR01DK100081 · NIDDK · MAYO CLINIC ROCHESTER · PI LERMAN, LILACH O, TEXTOR, STEPHEN C · 2014 to 2018
$2.8M
Obesity-induced mesenchymal stem cell senescenceR01DK120292 · NIDDK · MAYO CLINIC ROCHESTER · PI LERMAN, LILACH O · 2019 to 2022
$2.6M
Quantitative magnetization transfer MRI for evaluation of renal fibrosisR01DK122734 · NIDDK · MAYO CLINIC ROCHESTER · PI LERMAN, LILACH O · 2020 to 2023
$2.2M
Role of mitochondrial microRNAs (mitomiRs) in endogenous renal repairR01DK129240 · NIDDK · MAYO CLINIC ROCHESTER · PI Alfonso Eirin · 2023 to 2026
$1.8M
Noninvasive Evaluation of Renal Allograft Fibrosis by MRIR21AG062104 · NIA · MAYO CLINIC ROCHESTER · PI LERMAN, LILACH O · 2020 to 2021
$414k
Role of mitochondrial microRNAs (mitomiRs) in endogenous renal repairR56DK129240 · NIDDK · MAYO CLINIC ROCHESTER · PI EIRIN, ALFONSO · 2021 to 2021
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Renovascular Disease and Mitochondrial Dysfunction in Human Mesenchymal Stem Cells. · full record | OpenQuestion